Canaccord Genuity Group restated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) in a research note released on Wednesday, Benzinga reports. Canaccord Genuity Group currently has a $10.00 price objective on the biotechnology company’s stock.
Several other equities analysts have also issued reports on MCRB. StockNews.com lowered Seres Therapeutics from a hold rating to a sell rating in a research note on Tuesday, August 13th. Oppenheimer restated a market perform rating on shares of Seres Therapeutics in a research report on Friday, June 7th. Finally, Chardan Capital restated a buy rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday.
Get Our Latest Research Report on MCRB
Seres Therapeutics Trading Down 0.6 %
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.08. During the same period last year, the firm earned $0.36 earnings per share. As a group, sell-side analysts forecast that Seres Therapeutics will post -1.03 EPS for the current year.
Insider Activity
In other news, insider Teresa L. Young sold 24,480 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $1.08, for a total value of $26,438.40. Following the transaction, the insider now directly owns 78,178 shares of the company’s stock, valued at approximately $84,432.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is owned by company insiders.
Institutional Trading of Seres Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in shares of Seres Therapeutics in the fourth quarter valued at approximately $73,000. Handelsbanken Fonder AB grew its holdings in shares of Seres Therapeutics by 10.0% in the fourth quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock valued at $1,540,000 after acquiring an additional 100,000 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Seres Therapeutics by 668.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 33,135 shares in the last quarter. Pennant Investors LP bought a new position in shares of Seres Therapeutics in the fourth quarter valued at approximately $409,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Seres Therapeutics in the first quarter valued at approximately $39,000. 59.34% of the stock is owned by institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Read More
- Five stocks we like better than Seres Therapeutics
- What is an Earnings Surprise?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 8/12 – 8/16
- 3 Small Caps With Big Return Potential
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.